2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-136271
    MJ33 137300-78-8 98%
    MJ-33 is a competitive phospholipase A₂ (PLA₂) inhibitor. MJ-33 inhibits the activation of NOX2 by blocking the PLA₂ activity of Prdx6, thereby reducing the production of ROS. MJ-33 effectively inhibits the activity of acidic PLA₂ (pH 4.0), reduces the degradation of pulmonary surfactant phosphatidylcholine (PC), but has no effect on alkaline PLA₂ (pH 8.5). MJ-33 significantly alleviates lung oxidative damage induced by ischemia-reperfusion (I/R). MJ-33 significantly inhibits the invasive, migratory and adhesive abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 can be used to study ROS-related diseases and prostate cancer.
    MJ33
  • HY-136347
    3α-Hydroxy pravastatin sodium 81093-43-8 99.35%
    3α-Hydroxy pravastatin sodium is the major metabolite of Pravastatin. Pravastatin is a competitive HMG-CoA reductase inhibitor.
    3α-Hydroxy pravastatin sodium
  • HY-136501
    MRS2395 491611-55-3 98%
    MRS2395, an dipivaloyl derivative, is a potent P2Y12 receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a Ki of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC50 of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6.
    MRS2395
  • HY-136511
    Epicaptopril 63250-36-2 98%
    Epicaptopril (SQ 14534) is the derivative of Captopril (HY-B0368). Epicaptopril is an inhibitor for angiotensin-converting enzyme (ACE). Epicaptopril enhances vasodilation in an endothelium-derived relaxing factor (EDRF)-dependent manner. Epicaptopril is a free radical scavenger, and can be used in research about oxidative stress and free radical damage caused cardiovascular disorders.
    Epicaptopril
  • HY-136625
    LY134046 71274-97-0 98%
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT) with cardiovascular activity. LY134046 causes sustained reductions in mean arterial blood pressure and heart rate, but no significant reductions in norepinephrine concentrations in the rat brain. LY134046 does not interact with adrenergic or cholinergic receptors, and its hypotensive and bradycardic effects do not require neurogenic tension. LY134046 (40 mg/kg/day) causes sustained and significant inhibition of hypothalamic and brainstem NMT activity, resulting in central norepinephrine depletion.
    LY134046
  • HY-136677
    Lnd 796 118549-42-1 98%
    LND 796 is an aminosteroidal derivative with positive inotropic effects similar to those of digitalis. It exhibits electrophysiological, toxic, and inotropic effects in normal and partially potassium-depolarized ventricular muscles. LND 796 requires higher concentrations than digoxin to induce the same toxic symptoms. It exhibits a concentration-dependent positive inotropic effect on guinea pig papillary muscles in normal potassium solution. In partially potassium-depolarized papillary muscles, LND 796 enhances both components of contraction and increases the amplitude of slow action potentials. The mechanism of positive inotropic action of LND 796 involves enhanced calcium entry in calcium channels and inhibition of sodium-potassium ATPase. Due to its expanded positive inotropic range, LND 796 may have potential application in the treatment of congestive heart failure.
    Lnd 796
  • HY-136778
    INH2BP 137881-27-7 98%
    INH2BP is a poly(ADP-ribose) polymerase (PARP) inhibitor with antioxidant and anti-apoptotic activities. INH2BP reduces the production of intracellular reactive oxygen species (ROS), modulates the expression of apoptosis-related proteins such as Bax, Bcl-2 and cleaved caspase-3 and enhances cell survival through the activation of the ERK1/2 and p38 MAPK signaling pathways. INH2BP is promising for research of cardiovascular diseases.
    INH2BP
  • HY-136791
    BN52115 120908-94-3 98%
    BN 52115, a platelet-activating factor antagonist, has demonstrated the ability to mitigate bronchopulmonary changes in vivo.
    BN52115
  • HY-136876
    AHR-12234 citrate 125651-31-2 98%
    AHR-12234 citrate is an orally active antiarrhythmic agent. AHR-12234 citrate is effective against arrhythmias caused by abnormal automaticity, triggered activity, and reentry.
    AHR-12234 citrate
  • HY-136901
    Fusarochromanone 802915-53-3 98%
    Fusarochromanone (FC-101) is a fungal metabolite with potent anti-angiogenic and anti-cancer activity. Fusarochromanone-activated JNK pathway is attributed to induction of reactive oxygen species (ROS).
    Fusarochromanone
  • HY-136903
    SNJ-1945 854402-59-8 98%
    SNJ-1945 is an orally active Calpain inhibitor that can cross the blood-brain barrier. SNJ-1945 protects rat hearts against cardiac arrest-reperfusion injury by inhibiting the hydrolysis of α-fodrin. SNJ-1945 inhibits VEGF-induced angiogenesis in retinal endothelial cells. SNJ-1945 also protects SH-SY5Y cells from damage induced by MPP+ (HY-W008719) and Rotenone (HY-B1756). SNJ-1945 exhibits anti-inflammatory and neuroprotective activities in a mouse model of multiple sclerosis. SNJ-1945 can be used for the research of cardiovascular, nervous system and inflammatory diseases.
    SNJ-1945
  • HY-136995
    AFD-21 maleate 99465-44-8 98%
    AFD-21 maleate is a drug with antiarrhythmic activity. AFD-21 maleate inhibits sodium channels by binding to sodium channels in an inactive state, with both use-dependent and voltage-dependent effects. The unbinding rate of AFD-21 maleate is similar to that of Class I antiarrhythmic drugs with moderate kinetics. AFD-21 maleate can cause a slight prolongation of the action potential duration and significantly reduce the maximum rise rate of the action potential at certain concentrations. AFD-21 maleate also showed use-dependent blocking effects as stimulation frequency increased.
    AFD-21 maleate
  • HY-137024
    15-Keto-PGA1 61600-67-7 98%
    15-Keto-PGA1 is a metabolite of PGA1 and has significant vasoconstrictive effects. PGA1 is also a vasoconstrictor and is more potent than equivalent doses of prostaglandin F2α (PGF2α) and angiotensin II.
    15-Keto-PGA1
  • HY-137188
    Perindopril acyl-β-D-glucuronide 120398-66-5 98%
    Perindopril acyl-β-D-glucuronide is a metabolite of Perindopril (HY-B0130). Perindopril is an ACE inhibitor.
    Perindopril acyl-β-D-glucuronide
  • HY-137227
    15(R)-PTA2 71154-83-1 98%
    15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase.
    15(R)-PTA2
  • HY-137270
    16,16-Dimethyl PGA2 41691-92-3 98%
    16,16-Dimethyl PGA2 is an orally active prostaglandin analog with a prolonged in vivo half-life. 16,16-Dimethyl PGA2 can be used to study hypertension.
    16,16-Dimethyl PGA2
  • HY-137288
    17-Phenyl-18,19,20-trinor-PGD2 85280-91-7 98%
    17-Phenyl-18,19,20-trinor-PGD2 (17-Phenyl-PGD2) is an analogue of prostaglandin D2 (PGD2; HY-101988). 17-Phenyl-18,19,20-trinor-PGD2 is a potent inhibitor of platelet aggregation caused by aenosine diphosphate (ADP), with the IC50 of 8.4 μM (PGD2 IC50 = 18.6 nM). 17-Phenyl-18,19,20-trinor-PGD2 is a weak agonist of cyclic AMP accumulation.
    17-Phenyl-18,19,20-trinor-PGD2
  • HY-137355
    15(S)-15-methyl Prostaglandin D2 85280-90-6 98%
    15(S)-15-methyl Prostaglandin D2 (15(S)-15-methyl PGD2) is a metabolically stable synthetic analog of PGD2. In contrast to PGD2, 15(S)-15-methyl PGD2 induces vasoconstriction and increases systemic blood pressure with much reduced inhibitory activity on ADP-induced platelet aggregation. It also exhibits strong antifertility activity in hamsters (200-fold more potent than PGD2).
    15(S)-15-methyl Prostaglandin D2
  • HY-137364
    Disulfamide 671-88-5 98%
    Disulfamide, an orally active diuretic, is a carbonic anhydrase inhibitor with the IC50 value of 0.07 μM. Disulfamide leads to diuresis by inhibiting carbonic anhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal tubule.
    Disulfamide
  • HY-137387
    Carvedilol Glucuronide 114869-83-9 98%
    Carvedilol Glucuronide is the metabolite of Carvedilol (HY-B0006). Carvedilol (BM 14190) is an antagonist for β/α-1 adrenergic receptor. Carvedilol inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol is an antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome.
    Carvedilol Glucuronide
Cat. No. Product Name / Synonyms Application Reactivity